CLEVELAND--(BUSINESS WIRE)--Arteriocyte announced today a $4.99 Million award from the Ohio Third Frontier Commission’s Research Commercialization Program. The award will be used to expand clinical applications for Arteriocyte’s commercially available Magellan Platelet Rich Plasma (PRP) and bone marrow derived stem cell product “STEM-PREP” and will further the company’s development of its NANEX stem cell expansion technology for Blood Pharming.
